Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
2021 · Annals of Oncology · 265 citations
https://doi.org/10.1016/j.annonc.2021.02.017
P
Peter Lim
BC Cancer Agency(CA)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
94
Papers
1.3K
Citations
16
h-index
21
i10-index
Peter Lim is an academic researcher from BC Cancer Agency. The author has contributed to research in topics: Endometrial and Cervical Cancer Treatments & Ovarian cancer diagnosis and treatment & Uterine Myomas and Treatments. The author has an h-index of 16, co-authored 80 publications.
ORCID: 0000-0001-9714-1595Papers by this author
worksFeasibility and early oncologic outcomes of Total Intracorporeal Robotic Radical Hysterectomy with Vaginal Cerclage (TIRRHVC) for the treatment of clinical stage IB cervical cancer: A tumor containment technique
2024 · Gynecologic Oncology Reports · 2 citations
https://doi.org/10.1016/j.gore.2024.101437
LBA32 A randomized, phase II, dose optimization of gotistobart, a pH-sensitive anti-CTLA-4, in combination with standard dose pembrolizumab in platinum-resistant recurrent ovarian cancer: Safety, efficacy and dose optimization (PRESERVE-004/GOG-3081)
2024 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2024.08.2271
Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066)
2025 · Gynecologic Oncology · 0 citations
https://doi.org/10.1016/j.ygyno.2025.03.060
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat